New Treatment for Fragile X Syndrome by Correcting a Gene Mistake
Official title: Therapeutic Potential of Rescued FMR1 Mis-Splicing in Fragile X Syndrome
Funded at Univ of Massachusetts Med Sch Worcester · NIH-11093322 · Data updated 2026-11-12
This research explores a new way to treat Fragile X Syndrome by fixing a specific error in the FMR1 gene using special genetic tools.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Massachusetts Med Sch Worcester NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $418,750 |
| NIH project number | 5R01NS132935-03 |
| Project ID | NIH-11093322 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is relevant for individuals diagnosed with Fragile X Syndrome, particularly those whose FMR1 gene shows the specific mis-splicing error identified in this work.
✕Less likely to help
Patients with Fragile X Syndrome whose FMR1 gene does not exhibit this particular mis-splicing error may not benefit from this specific therapeutic approach.
What this research studies
Fragile X Syndrome is a common inherited cause of intellectual disability and autism, caused by a problem with the FMR1 gene that stops it from working correctly. Our team discovered that in some people with Fragile X, the FMR1 gene makes a faulty, mis-spliced RNA molecule. We are developing special genetic tools called antisense oligonucleotides (ASOs) that can correct this mistake. By fixing the mis-splicing, we hope to restore the FMR1 gene's normal function and reduce the symptoms of the syndrome.
Why it matters
Potential benefit: If successful, this approach could lead to a new therapy that directly addresses the genetic cause of Fragile X Syndrome, potentially improving intellectual function and reducing autism-like behaviors.
How similar studies have gone: Antisense oligonucleotide (ASO) therapies have shown success in treating other genetic disorders, but this specific application to correct FMR1 mis-splicing in Fragile X Syndrome is a novel approach.
Where this research is happening
-
Univ of Massachusetts Med Sch Worcester
Worcester, United States Active
Researchers
- Principal investigator: Richter, Joel D — Univ of Massachusetts Med Sch Worcester
- Study coordinator: Richter, Joel D
Related research
Other NIH-funded projects on the same topics.
-
Understanding Fragile X Syndrome: How it progresses and affects daily life
A long-term study using existing Fragile X data to map how the condition changes over time in children and young adults, including how autism, race, and location influence outcomes.
-
Sleep and mood links in Fragile X Syndrome
A short, patient-friendly study to understand how sleep problems relate to mood and depressive symptoms in people with Fragile X–linked autism.
-
Connecting 3D genome misfolding to gene silencing in Fragile X syndrome
A study in people with Fragile X syndrome focuses on how 3D genome folding errors may turn off important genes, contributing to the condition’s features.
-
Cortical circuit problems in Fragile X mice and people
Researchers are studying how brain circuits go awry in Fragile X syndrome by comparing mice and people to understand why certain brain rhythms and responses are altered.
-
Brain biology in fragile X syndrome: how brain signals unfold and vary in patients
This grant supports research to understand brain signals and why symptoms vary in people with fragile X syndrome, aiming to translate findings into better care.
-
Brain research on Fragile X Syndrome to improve therapies
A multi-year program studies brain function and differences in Fragile X Syndrome to help develop better treatments for people with FXS.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.